ZW-191 is under clinical development by Zymeworks and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ZW-191’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ZW-191 overview
ZW-191 is under development for the treatment of solid tumor types including epithelial ovarian cancer, endometrial cancer and non-small cell lung cancer (NSCLC). The drug candidate is an antibody drug conjugate bearing a topoisomerase 1 inhibitor payload (ZD06519) which acts by targeting FOLR1 alpha receptor. It is being developed based on Zymelink technology platform. It is administered by intravenous route.
It was also under development for the treatment of triple negative breast cancer.
Zymeworks overview
Zymeworks is a clinical-stage biotechnology company that develops novel and multifunctional biotherapeutics. It utilizes Azymetric, Zymelink, EFECT, Protect and T Cell Engagers technology platforms to develop drugs. The company’s pipeline products include zanidatamab, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2) that treats gastroesophageal adenocarcinomas, biliary tract, gastrointestinal and breast cancer; and zanidatamab zovodotin is a HER2-targeted bispecific antibody-drug conjugate (ADC) for expressing cancers. Its preclinical products include ZW191, ZW171, ZW251 and ZW220 targeting ovarian, endometrial and lung and liver cancers and hepatocellular carcinoma, among others. The company operates through its subsidiaries in the US, Ireland, Canada, the UK and Singapore. Zymeworks is headquartered in Vancouver, British Columbia, Canada.
For a complete picture of ZW-191’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
